From Nasdaq: 2025-04-15 19:54:00

Kraig Biocraft Laboratories, Inc. has introduced a next-generation gene-splicing and molecular biology platform. This breakthrough enhances the company’s ability to engineer advanced spider silk and other high-performance materials. Using cutting-edge gene editing tools, the platform allows for faster, more precise DNA manipulation. Kraig Labs has already created a new transgenic silkworm, undergoing testing for commercial use. CEO Kim Thompson sees this as a transformative step for the company’s genetic engineering program, with plans to adopt the platform for all future silkworm development. The company is now focusing all biotechnology efforts on this new platform to improve efficiency, reliability, and silk performance. On Tuesday, KBLB closed at $0.085 on the OTC Markets OTCQB.



Read more at Nasdaq: Kraig Labs Unveils Next-Gen Gene-Splicing Platform To Advance Spider Silk Development